New drug etrinabdione tested for leg artery disease
NCT ID NCT06774040
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase IIa trial tests the safety and tolerability of a new drug called etrinabdione in 30 adults with peripheral arterial disease (PAD). Participants take the drug twice daily for 12 months, starting with a low dose and possibly moving to a higher dose if safe. Researchers will also check if the drug improves blood flow and walking ability.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- etrinabdione
- What this could lead to
- If successful, this could point toward a new treatment option for peripheral arterial disease that improves blood flow and walking ability.
- What could go wrong
- This is an early, small Phase IIa trial with only 30 participants. It primarily tests safety, not effectiveness, and the higher dose may be stopped if safety concerns arise.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL ARTERIAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital Universitario Reina Sofía
Córdoba, 14014, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Beetroot juice may boost heart blood flow and walking in leg artery disease
- Can a Pre-Surgery skin coating stop wound infections?
- Can a 'Scoring' balloon unclog leg arteries better and reduce stents?
- Can a temporary stent keep leg arteries open?
- Can a Lab-Grown artery graft outlast current options?
- Can a phone app replace cardiac rehab? a new trial puts digital heart care to the test